CAR-NK cell therapy: promise and challenges in solid tumors
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Over the past few years, cellular immunotherapy has emerged as a promising treatment for certain hematologic cancers, with various CAR-T therapies now widely used in clinical settings. However, challenges related to the production of autologous cell products and the management of CAR-T cell toxicity highlight the need for new cell therapy options that are universal, safe, and effective. Natural killer (NK) cells, which are part of the innate immune system, offer unique advantages, including the potential for off-the-shelf therapy. A recent first-in-human trial of CD19-CAR-NK infusion in patients with relapsed/refractory lymphoid malignancies demonstrated safety and promising clinical activity. Building on these positive clinical outcomes, current research focuses on enhancing CAR-NK cell potency by increasing their in vivo persistence and addressing functional exhaustion. There is also growing interest in applying the successes seen in hematologic malignancies to solid tumors. This review discusses current trends and emerging concepts in the engineering of next-generation CAR- NK therapies. It will cover the process of constructing CAR-NK cells, potential targets for their manufacturing, and their role in various solid tumors. Additionally, it will examine the mechanisms of action and the research status of CAR-NK therapies in the treatment of solid tumors, along with their advantages, limitations, and future challenges. The insights provided may guide future investigations aimed at optimizing CAR-NK therapy for a broader range of malignancies.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- CAR-NK cell therapy: promise and challenges in solid tumors
- Date Crossref
- 07/04/2025
- Éditeur
- Frontiers Media SA
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Insubria Immunology and General Pathology Laboratory pays non établi dans la noticeUniversité ou école supérieure
-
Istituto Oncologico Veneto pays non établi dans la noticeÉtablissement de santé
-
Istituti di Ricovero e Cura a Carattere Scientifico pays non établi dans la noticeÉtablissement de santé
-
University of Padua pays non établi dans la noticeUniversité ou école supérieure
-
Veneto Institute of Oncology IOV - IRCCS Immunology and Molecular Oncology Unit pays non établi dans la noticeStructure de recherche
-
University of Padova Department of Surgery pays non établi dans la noticeUniversité ou école supérieure
Immunology and General Pathology Laboratory — University of Insubria, Istituto Oncologico Veneto et Istituti di Ricovero e Cura a Carattere Scientifico, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.